Coronary heart disease is the most
common killer United States and Europe. Acute coronary syndrome (ACS), a common
complication of coronary heart disease, is associated with more than 2.5
million hospitalizations worldwide each year. Medicure Inc. is a specialty
pharmaceutical company that directs its attention in areas that fight back
these staggering numbers through its research, clinical development and
commercialization of human therapeutics.
The company has raised over $140
million and has allocated it toward the clinical development of cardiovascular
drugs. In 2006 Medicure acquired the USA commercial rights to the
cardiovascular drug, AGGRASTAT (tirofiban HCl), originally developed by Merck.
AGGRASTAT (an antiplatelet medicine that prevents blood clots from forming),
along with Heparin, is indicated for the treatment of acute coronary syndrome.
Medicure’s builds value for its shareholders by generating revenue to support
operations and make investments in the drug’s clinical advancement.
The company’s central focus is on
the US commercial sales of FDA-approved small molecule, AGGRASTAT, and
leverages the company’s experienced commercial team to facilitate bringing it
to market. As of late, there is renewed interest in the drug coming from
hospitals and clinicians as a result of notable clinical and economic data.
Furthermore, Aggrastat is indicated to reduce the rate of thrombotic cardiovascular
events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
The US rights to Aggrastat are
owned by Medicure’s subsidiary, Medicure International, Inc. (Barbados) and the
product is distributed in the United States by Medicure’s US subsidiary,
Medicure Pharma, Inc. The company sees small molecule development opportunities
as one would conclude from MCUJF’s current development programs in the
neurology and cardiology fields.
For more information on the company
visit www.medicure.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
